Stocks · News reference

Boston Scientific Exec Says Co. Is Re-Evaluating 2027 Framework In Light Of The Cyber Incident And Will Provide A Preview On October; Co. Is Executing A Significant Restructuring Plan That Will Provide Some Financial Benefit

Sep 10, 2026, 12:41 PMBenzinga Newsdesk

https://event.summitcast.com/view/aMepMFxWv3z5SRZ9meKJzp/PR377yhtGDwnuWjurFvZmp

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 10, 2026, 4:16 PMTim Melvin
Alpha Buying: 4 Falling Knives Insiders Are Buying
There are dozens of reasons corporate executives sell shares. They may need money to pay taxes, buy a house, settle a divorce, diversify their wealth, or fund a new boat they will use three times before deciding they
AMRZ BSX CDNL GBFH
BenzingaSep 9, 2026, 1:04 PMAvi Kapoor
Imax To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts cut targets for CAN, TTAN and BSX, while raising targets for BRZE, VRNS, IMAX, PHVS and CHYM. Ratings largely remained positive.
ABM BRZE BSX CAN CHYM
BenzingaSep 9, 2026, 11:22 AMBenzinga Newsdesk
BTIG Maintains Buy on Boston Scientific, Lowers Price Target to $56
BTIG analyst Marie Thibault maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $60 to $56.
BSX